Form 4: BioCardia CFO David McClung Reports Stock Transactions
SEC Form 4 Filing
BioCardia's Chief Financial Officer, David McClung, reports the acquisition and disposal of common stock related to vested restricted stock units.
Summary
- On October 11, 2024, David McClung, the CFO of BioCardia, Inc., acquired 24,193 shares of common stock at $2.65 per share related to restricted stock units (RSUs) that vested.
- On the same day, 11,565 shares were withheld by BioCardia to cover income tax obligations related to the RSU vesting.
- Following these transactions, McClung directly owns 30,008 shares of common stock.
- The RSUs vested 100% on October 11, 2024, and each RSU represents the right to receive one share of BioCardia's common stock.
- The withholding of shares by the issuer does not represent a sale by the reporting person.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it reflects routine stock transactions related to executive compensation. There are no explicit positive or negative implications for the company's performance.
Positives
- The vesting of RSUs indicates that McClung has met certain performance or time-based requirements, aligning his interests with the company's success.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, ensuring transparency and compliance with SEC regulations.
Comparison to Industry Standards
- Similar filings are common across publicly traded companies, such as those by executives at Medtronic or Boston Scientific, when they exercise stock options or RSUs.
- The number of shares involved and the transaction price are specific to BioCardia and its compensation structure.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect changes in insider ownership.
- Employees holding RSUs may be interested in the vesting schedule and tax implications.
Key Dates
| Date | Description |
|---|---|
| 10/11/2024 | Date of earliest transaction, RSU vesting, and share acquisition/disposal. |
| 10/16/2024 | Date of signature for the Form 4 filing. |
Keywords
BioCardia, BCDA, David McClung, CFO, Form 4, Stock, Restricted Stock Units, RSU, Beneficial Ownership, Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.